Project Grant R01HL174649
Award Date
9/1/25
Completion Date
5/31/29
Dollars Obligated
$688K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This $607,952 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pittsburgh to investigate indole metabolites as novel danger signals that activate regulated cell death pathways in lung epithelial cells, which may contribute to the pathogenesis of acute respiratory distress syndrome (ARDS). The key research objectives include...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $480,990 to the University of Illinois for a research project focused on accelerating alveolar epithelial regeneration to treat acute respiratory distress syndrome (ARDS). The key objectives are to investigate the role of "aerocytes", a newly identified capillary endothelial cell population, in regulating alveolar...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $188,740 to the University of Pittsburgh to conduct research on the impact of glycocalyx degradation on acute respiratory distress syndrome (ARDS) pathogenesis and outcomes. The research aims to: 1) estimate the attributable impact of glycocalyx degradation on ARDS patient outcomes, and 2) determine the longitudinal relationship between glycocalyx degradation...
This Project Grant award of $775,992.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at the University of North Carolina at Chapel Hill to investigate the role of regulatory T cells (Tregs) and glucocorticoid signaling in the resolution of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The research aims to determine how glucocorticoid signaling through Tregs impacts their immunomodulatory and tissue...
This $782,362 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of TREK-1 potassium channels in acute respiratory distress syndrome (ARDS). The key objectives are to: 1) determine if ARDS decreases epithelial and endothelial TREK-1 levels, leading to cell membrane depolarization and calcium-dependent inflammation, and 2) evaluate if activating residual TREK-1...
This federal Project Grant award of $200,502 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a research project led by Dr. Narges Alipanah-Lechner at the University of California, San Francisco (UCSF). The project aims to identify metabolite and protein drivers of the evolution of Acute Respiratory Distress Syndrome (ARDS) subtypes, specifically the hyper-inflammatory and hypo-inflammatory forms. The research will utilize comprehensive...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $189,000 to the University of Colorado-Denver to investigate the role of aldehyde dehydrogenase 2 (ALDH2) in pulmonary fibrosis following acute lung injury and acute respiratory distress syndrome (ARDS). The 2-year research project aims to elucidate the mechanisms by which ALDH2 impacts fibrogenesis in lung cells and evaluate the...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $696,473 to the University of Pittsburgh to investigate the role of gut dysbiosis and bile acid metabolism in driving obesity-associated asthma. The research aims to (1) determine how dysregulated bile acid metabolism and TMAO signaling contribute to airway hyperresponsiveness, (2) examine if altered gut microbial function exacerbates disease severity, and (3)...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,831,848 to the University of Rochester to investigate how neonatal microbiome colonization impacts lung immunity and regeneration. The research aims to elucidate how early-life microbial dysbiosis remodels the developmental program in lung-resident lymphocytes and epithelial cells, contributing to chronic respiratory disease. Key...
This $186,408 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research to evaluate CD14 as a potential therapeutic target for acute respiratory distress syndrome (ARDS). The project aims to: 1) determine the effects of the CD14-blocking antibody IC14 on cellular targets through blood leukocyte RNA sequencing analysis, 2) examine the relationship between the CD14-pathway biomarker presepsin...